LEAP-010 (NCT04199104) was another randomized control trial comparing pembrolizumab monotherapy to its combination with lenvatinib as first line therapy for PD-L1 positive R/M SCCHN patients, though a recent press release indicated that the trial was closed based on lack of observed significant difference in the primary endpoint of overall survival. Here, CD274 is linked to head and neck squamous cell carcinoma.